Back to top
more

Alkermes (ALKS)

(Delayed Data from NSDQ)

$29.24 USD

29.24
1,523,282

+0.01 (0.03%)

Updated Nov 13, 2024 04:00 PM ET

After-Market: $29.24 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

4 Biotech Stocks With Bright Prospects to Buy Amid Recovery

New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position ALKS, GERN, IMCR and BLU well amid the volatility.

Abbott (ABT) Medical Devices Arm Gains Traction, FX Woe Stays

Within Abbott's (ABT) Nutrition arm, while the pediatric nutrition business witnesses a drag, the adult nutrition business continues to perform well.

Amedisys (AMED) Contessa's New JV Broadens At-Home Care Range

Amedisys' (AMED) latest initiative aims at providing patients with a high-quality continuum of care in the home.

Thermo Fisher's (TMO) Autoimmune Disease Test Gets FDA Nod

Thermo Fisher's (TMO) RNA Polymerase III and EliA Rib-P blood tests are intended to diagnose systemic sclerosis and systemic lupus erythematosus.

Moderna's (MRNA) Omicron-Specific Booster Jab Meets Study Goal

Moderna's (MRNA) bivalent COVID booster candidate targeting the Omicron variant achieved all pre-specified endpoints in a phase II/III study.

Rigel (RIGL) wAIHA Study Fails to Meet Goals, Stock Tanks

Rigel (RIGL) phase III study evaluating fostamatinib in patients with warm autoimmune hemolytic anemia did not demonstrate statistical significance in the primary efficacy endpoint.

PerkinElmer's (PKI) Latest Launch to Expand Food Safety Suite

PerkinElmer's (PKI) microbial plates minimize human error by providing standardized protocols and offer a small footprint to save space in incubators and storage areas.

Vertex (VRTX) Kidney Drug Gets FDA Breakthrough Designation

Vertex (VRTX) inaxaplin is being evaluated in a single-phase II/III pivotal study in patients with AMKD with two APOL1 mutations and proteinuric kidney disease.

bluebird (BLUE) Up as FDA Nod Likely for Thalassemia Therapy

Based on briefing documents issued by the FDA, a positive regulatory approval is expected on bluebird bio's (BLUE) gene-therapy for treating thalassemia.

Mirati (MRTX) Up on Positive Data From NSCLC Study on Adagrasib

Mirati (MRTX) gains on positive results from an early stage KRYSTAL-1 study on experimental candidate adagrasib for lung cancer.

Bruker (BRKR) to Advance 4D Proteomics With Latest Launch

Bruker's (BRKR) timsTOF HT is enhanced for high-throughput, deep and unbiased plasma proteomics, and liquid biopsy biomarker research.

Sanofi's (SNY) Dupixent Gets FDA Nod for Eczema in Infants

Sanofi (SNY) and partner Regeneron's label expansion application for Dupixent to include infants with moderate-to-severe atopic dermatitis gets FDA approval.

Tandem Diabetes (TNDM) Posts Positive Control-IQ Study Data

Data presented at the ADA conference demonstrates Tandem Diabetes' (TNDM) Control-IQ technology's ability to make a positive and sustained impact across a diverse group of people with diabetes.

Here's Why You Should Hold on to NuVasive (NUVA) Stock for Now

Investors are optimistic about NuVasive (NUVA) on strong sales performance across the U.S. spinal hardware and the U.S. surgical support product lines.

Intercept (ICPT) Announces Delay in Meeting With the FDA

Intercept (ICPT) faces yet another setback as its resubmission for NDA for OCA for NASH gets delayed.

Emergent (EBS) Stock Down as J&J Ends COVID-19 CDMO Contract

Emergent (EBS) sends contract breach notice to J&J, following the latter's decision to end their contract for CDMO services for its COVID-19 vaccine. J&J also cites contract breach as the basis for termination.

Biogen (BIIB) Inks Deal for Alectos' Parkinson's Disease Drug

Biogen (BIIB) signs a deal with privately-held Alectos Therapeutics to gain an exclusive global license to the latter's pre-clinical oral selective GBA2 inhibitor, AL01811, targeting Parkinson's disease.

AstraZeneca (AZN) Breast Cancer Drug Cuts Risk of Death to Half

Data from a late-stage study shows that AstraZeneca's (AZN) Enhertu meets superior and clinically meaningful progression-free survival and overall survival in HER2-low metastatic breast cancer patients.

Bristol Myers (BMY) to Acquire Turning Point, Withdraws sBLA

Bristol Myers (BMY) is set to acquire Turning Point to bolster its oncology portfolio. The company also withdraws its sbLA for Reblozyl.

Bio-Rad (BIO) Immunohematology Arm Recovers, New Launches Aid

Bio-Rad's (BIO) qPCR business is experiencing excellent uptake from the new-generation CFX Opus platform.

Boston Scientific (BSX) Gains from New Buyouts, FX Issue Ails

Boston Scientific (BSX) is currently looking forward to launching its arterial and venous offerings in the second half of 2022.

Has Aclaris Therapeutics (ACRS) Outpaced Other Medical Stocks This Year?

Here is how Aclaris Therapeutics (ACRS) and Alkermes (ALKS) have performed compared to their sector so far this year.

Abbott (ABT) FreeStyle Libre 3 System's Study Outcome Favorable

Abbott's (ABT) FreeStyle Libre 3 system is the first and only 14-day CGM system with an overall MARD of 7.9%.

Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now

Investors are optimistic about Quest Diagnostics (DGX) on a strong recovery in the base business and the raised 2022 outlook.

BMY, IMTX Extend Deal to Develop Cell Therapies for Cancer

Bristol Myers (BMY) strengthens its partnership with the small biotech company Immatics (IMTX) to develop multiple allogenic cell therapies targeting multiple cancer indications.